290354-26-6

Basic information

• Product Name: C₂₈H₄₂N₄O₂
• CAS NO: 290354-26-6
• Molecular Weight: 466.667
• Mol File: 290354-26-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₂₈H₄₂N₄O₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₈H₄₂N₄O₂(290354-26-6)
• EPA Substance Registry System: C₂₈H₄₂N₄O₂(290354-26-6)

Safety Data

• Hazardous Substances Data: 290354-26-6(Hazardous Substances Data)

Upstream product

• 86447-11-2 1-tert-butoxycarbonyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid 
• 290354-23-3 N'-t-butoxycarbonyl-N,N-diethyl-3,4-dehydronipecotamide 
• 290354-27-7 N'-vinyloxycarbonyl-N,N-diethyl-3,4-dehydronipecotamide 
• 300-08-3 arecoline hydrobromide 
• 6027-91-4 1,2,5,6-tetrahydro-3-pyridinecarboxylic acid hydrochloride 
• 26070-52-0 N'-methyl-N,N-diethyl-3,4-dehydronipecotamide 
• 63-75-2 arecoline 
• 59826-28-7 1-Methyl-1,2,5,6-tetrahydro-pyridine-3-carbonyl chloride 
• 499-04-7 1-methyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid 
• 623-24-5 1,4-bis(bromomethyl)benzene 
• 290354-24-4 N,N-diethyl-3,4-dehydronipecotamide 

Relevant articles and documents

New carbamoylpiperidines as human platelet aggregation inhibitors

A series of 3-carbamoylpiperidines (nipecotamides) are designed, synthesized and tested for their inhibitory action against adenosine diphosphate (ADP)-induced aggregation of human platelets. A structure- activity analysis of the bis(nipecotamido)aralkane type showed that a substituent on the piperidine ring should preferably be an amide and that the electronegativity of the carbonyl oxygen and the orientation of the amide group affected activities. Based on the knowledge of factors influencing platelet activation and aggregation, a nitric ester moiety which could release nitric oxide (NO) in situ, is incorporated into the nipecotamide structure. These compounds exhibit increased activity compared to those having no -ONO2 function. They also show stereoselectivity, with the meso isomer being approximately twice as potent as the synthetic diastereomeric mixture. Replacement of the -ONO2 function with hydroxyl, ester or alkyl groups considerably diminishes aggregation-inhibitory potential. Nipecotamides are shown here to inhibit the basal and collagen-induced rise in platelet inositol trisphosphate (IP3) levels, as well as phosphoinositide turnover. A comprehensive mechanism of action is proposed taking earlier results into consideration. (C) 2000 Elsevier Science Ltd.